Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a significant increase in short interest in August. As of August 14th, there was short interest totaling 51,809 shares, an increase of 205.1% from the July 30th total of 16,980 shares. Based on an average daily volume of 11,844,452 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.2% of the shares of the company are sold short.

Analysts Set New Price Targets

BJDX has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. Wall Street Zen upgraded shares of Bluejay Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Bluejay Diagnostics Stock Performance

Shares of NASDAQ:BJDX traded up $0.09 during midday trading on Friday, reaching $0.99. The company had a trading volume of 9,449,924 shares, compared to its average volume of 2,402,054. The company has a fifty day simple moving average of $1.41 and a two-hundred day simple moving average of $2.05. The firm has a market cap of $4.45 million, a price-to-earnings ratio of -0.14 and a beta of 0.89. Bluejay Diagnostics has a 1-year low of $0.83 and a 1-year high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3,520.00) by $3,518.88.

Insider Transactions at Bluejay Diagnostics

In related news, major shareholder Financial Lp Hrt bought 64,047 shares of the stock in a transaction on Thursday, July 9th. The shares were purchased at an average price of $1.51 per share, with a total value of $96,710.97. Following the purchase, the insider owned 126,993 shares in the company, valued at approximately $191,759.43. This represents a 101.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.